Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Rating) dropped 7.3% during mid-day trading on Friday . The stock traded as low as $0.26 and last traded at $0.28. Approximately 92,621 shares changed hands during trading, a decline of 69% from the average daily volume of 301,500 shares. The stock had previously closed at $0.30.
NeuroBo Pharmaceuticals Stock Down 7.3 %
The firm has a fifty day moving average price of $0.43 and a 200-day moving average price of $0.58. The firm has a market cap of $7.36 million, a price-to-earnings ratio of -0.49 and a beta of 0.49.
NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Rating) last posted its quarterly earnings data on Friday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. Equities research analysts anticipate that NeuroBo Pharmaceuticals, Inc. will post -0.7 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
NeuroBo Pharmaceuticals Company Profile
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19.
- Get a free copy of the StockNews.com research report on NeuroBo Pharmaceuticals (NRBO)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.